What is HC Wainwright’s Estimate for Insmed FY2027 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Equities research analysts at HC Wainwright raised their FY2027 EPS estimates for shares of Insmed in a research note issued to investors on Monday, October 12th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings of $1.63 per share for the year, up from their previous estimate of $1.62. HC Wainwright currently has a “Buy” rating and a $220.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.84) per share.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The business had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter last year, the company earned ($1.70) earnings per share. The firm’s revenue was up 296.1% on a year-over-year basis.

INSM has been the subject of a number of other research reports. BMO Capital Markets reiterated an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Evercore restated an “outperform” rating and set a $170.00 price objective on shares of Insmed in a research report on Friday, August 7th. Mizuho set a $192.00 price objective on Insmed in a research report on Tuesday, June 16th. UBS Group restated a “buy” rating on shares of Insmed in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $235.00 target price on shares of Insmed in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $200.30.

Insmed Trading Down 2.0%

Shares of INSM opened at $98.56 on Tuesday. The stock’s 50-day moving average price is $120.20 and its 200 day moving average price is $119.46. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $21.52 billion, a price-to-earnings ratio of -23.98 and a beta of 0.83. Insmed has a 12-month low of $90.39 and a 12-month high of $212.75.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently modified their holdings of the stock. Empowered Funds LLC lifted its stake in shares of Insmed by 32.6% during the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after acquiring an additional 12,775 shares during the period. Hsbc Holdings PLC increased its position in Insmed by 8,052.6% in the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock worth $21,493,000 after purchasing an additional 121,755 shares during the period. S&CO Inc. bought a new stake in Insmed during the 2nd quarter worth about $1,386,000. C WorldWide Group Holding A S raised its holdings in Insmed by 62.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock worth $27,840,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Insmed during the 4th quarter worth about $1,901,000.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David R. Brennan sold 25,000 shares of Insmed stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.